Antidepressant treatment with maprotiline in the management of emotional disturbances in patients with acute myocardial infarction: a controlled study.
In coronary artery disease the patients usually manifest both anxiety and depression disturbances. A controlled clinical study was conducted to test the efficacy of a new antidepressant agent, maprotiline, in the early stages of acute myocardial infarction. The sample consisted of 126 patients, sixty-three receiving orally 25 mg of maprotiline twice daily and the remainder 5 mg of diazepam twice daily. Treatment lasted on an average two weeks (ten days to eight weeks). The depressive and/or anxiety conditions were rated on the basis of a questionnaire administered before and after treatment. Depression improved markedly in patients receiving maprotiline, while the two drugs developed a comparable anxiolytic action. Tolerability was good. No clinical or ECG evidence of cardiotoxic signs was detected. The importance of a drug with these characteristics in the management of emotional disturbances in the early stages of coronary artery disease is emphasized.
D000208:Acute Disease; D000328:Adult; D000342:Affective Symptoms / Q000188:drug therapy*; D000368:Aged; D000873:Anthracenes / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy / Q000209:etiology; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy / Q000209:etiology; D003975:Diazepam / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D008376:Maprotiline / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications*; D011569:Psychiatric Status Rating Scales; D011795:Surveys and Questionnaires
D000873:Anthracenes; D000928:Antidepressive Agents; D008376:Maprotiline; D003975:Diazepam